Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, placebo controlled pivotal trial of Ezutromid in patients

Next Previous
X
Search
Trial Profile

A randomised, placebo controlled pivotal trial of Ezutromid in patients

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezutromid (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Sponsors Summit Therapeutics

    • Most Recent Events

    • 27 Jun 2018 According to a Summit Therapeutics media release, based on the results of the PhaseOut DMD 48-week data, the company has discontinued this drug development program, as, its primary and secondary endpoints has not been Met.
    • 27 Jun 2018 Status changed from planning to withdrawn prior to enrolment, according to a Summit Therapeutics media release.
    • 29 Jan 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top